

Elizabeth A Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/421679/publications.pdf>

Version: 2024-02-01

78
papers

2,866
citations

236925

25
h-index

182427

51
g-index

78
all docs

78
docs citations

78
times ranked

6029
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 1598-1605.	1.6	339
2	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	1.4	259
3	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016, 29, 574-586.	16.8	227
4	Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. <i>Cancer Discovery</i> , 2016, 6, 368-381.	9.4	215
5	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. <i>Cancer Discovery</i> , 2017, 7, 156-164.	9.4	164
6	Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. <i>Blood</i> , 2016, 128, 1093-1100.	1.4	126
7	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. <i>Cell Reports</i> , 2015, 12, 622-635.	6.4	123
8	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020, 38, 2380-2389.	1.6	110
9	Clinicopathologic Features and Prognostic Impact of Lymph Node Involvement in Patients With Breast Implant-associated Anaplastic Large Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 293-305.	3.7	80
10	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. <i>Nature Communications</i> , 2018, 9, 2024.	12.8	80
11	Cutaneous Radiation-Associated Angiosarcoma of the Breast: Poor Prognosis in a Rare Secondary Malignancy. <i>Annals of Surgical Oncology</i> , 2012, 19, 3801-3808.	1.5	76
12	Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia. <i>Cell Stem Cell</i> , 2017, 21, 547-555.e8.	11.1	71
13	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. <i>British Journal of Haematology</i> , 2015, 169, 851-858.	2.5	63
14	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2365-2376.	0.7	59
15	Antagonizing Integrin $\alpha 2 \beta 3$ Increases Immunosuppression in Cancer. <i>Cancer Research</i> , 2016, 76, 3484-3495.	0.9	58
16	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2199-2204.	5.2	52
17	IgM myeloma: A multicenter retrospective study of 134 patients. <i>American Journal of Hematology</i> , 2017, 92, 746-751.	4.1	45
18	Targeted inhibition of CD47-SIRP α requires Fc-Fc γ R interactions to maximize activity in T-cell lymphomas. <i>Blood</i> , 2019, 134, 1430-1440.	1.4	45

#	ARTICLE	IF	CITATIONS
19	Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. <i>Blood Advances</i> , 2019, 3, 1540-1545.	5.2	44
20	Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. <i>Cancer Discovery</i> , 2022, 12, 522-541.	9.4	44
21	Intergenerational epigenetic inheritance of cancer susceptibility in mammals. <i>ELife</i> , 2019, 8, .	6.0	43
22	Detection of activating <i>MAP2K1</i> mutations in atypical hairy cell leukemia and hairy cell leukemia variant. <i>Leukemia and Lymphoma</i> , 2017, 58, 233-236.	1.3	39
23	Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. <i>JCI Insight</i> , 2021, 6, .	5.0	39
24	Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. <i>Cancer Discovery</i> , 2019, 9, 944-961.	9.4	36
25	Immunohistochemical Detection of Hairy Cell Leukemia in Paraffin Sections Using a Highly Effective CD103 Rabbit Monoclonal Antibody. <i>American Journal of Clinical Pathology</i> , 2013, 139, 220-230.	0.7	30
26	Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features. <i>Blood Advances</i> , 2021, 5, 649-661.	5.2	26
27	Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma: An Underrecognized Aggressive Lymphoma. <i>Advances in Hematology</i> , 2012, 2012, 1-6.	1.0	25
28	Secondary cytogenetic abnormalities in core-binding factor AML harboring <i>inv(16)</i> vs <i>t(8;21)</i> . <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
29	<i>PAX8</i> and <i>PAX5</i> are differentially expressed in B-cell and T-cell lymphomas. <i>Histopathology</i> , 2013, 62, 406-413.	2.9	21
30	Clinical utility of targeted next-generation sequencing-based screening of peripheral blood in the evaluation of cytopenias. <i>Blood</i> , 2019, 134, 2222-2225.	1.4	21
31	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. <i>Blood</i> , 2015, 126, 497-497.	1.4	21
32	Lymphoma and Pathology in Sub-Saharan Africa. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 91-100.	1.4	20
33	Infectious Granulomatous Dermatitis Associated With <i>Rothia mucilaginosa</i> Bacteremia: A Case Report. <i>American Journal of Dermatopathology</i> , 2010, 32, 175-179.	0.6	18
34	NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders. <i>American Journal of Clinical Pathology</i> , 2019, 151, 75-85.	0.7	18
35	Core-binding factor acute myeloid leukemia with <i>t(8;21)</i> : Risk factors and a novel scoring system (iCBF) Tj ETQq 1 1 0.784314 rgBT	2.8	17
36	Contribution of clonal hematopoiesis to adult-onset hemophagocytic lymphohistiocytosis. <i>Blood</i> , 2020, 136, 3051-3055.	1.4	15

#	ARTICLE	IF	CITATIONS
37	Myeloid neoplasm demonstrating a <i>STAT5B-RARA</i> rearrangement and genetic alterations associated with all- <i>trans</i> retinoic acid resistance identified by a custom next-generation sequencing assay. <i>Journal of Physical Education and Sports Management</i> , 2015, 1, a000307.	1.2	13
38	Systematic STAT3 sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemia. <i>Blood Advances</i> , 2017, 1, 1786-1789.	5.2	13
39	Detection of the KITD816V mutation in myelodysplastic and/or myeloproliferative neoplasms and acute myeloid leukemia with myelodysplasia-related changes predicts concurrent systemic mastocytosis. <i>Modern Pathology</i> , 2020, 33, 1135-1145.	5.5	12
40	Imaging of IgG4-Related Disease in the Head and Neck: A Systematic Review, Case Series, and Pathophysiology Update. <i>Journal of Neuroradiology</i> , 2021, 48, 369-378.	1.1	11
41	Morphological and immunophenotypical features of hairy cell leukaemia involving lymph nodes and extranodal tissues. <i>Histopathology</i> , 2017, 71, 112-124.	2.9	10
42	Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 823-829.	1.3	10
43	Comprehensive metagenomic analysis of blastic plasmacytoid dendritic cell neoplasm. <i>Blood Advances</i> , 2020, 4, 1006-1011.	5.2	10
44	Proapoptotic protein BIM as a novel prognostic marker in mantle cell lymphoma. <i>Human Pathology</i> , 2019, 93, 54-64.	2.0	8
45	Identification of germline variants in adults with hemophagocytic lymphohistiocytosis. <i>Blood Advances</i> , 2020, 4, 925-929.	5.2	8
46	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. <i>Blood Advances</i> , 2016, 1, 84-92.	5.2	6
47	LIM domain only 2 (LMO2) expression distinguishes T _H lymphoblastic leukemia/lymphoma from indolent T _H lymphoblastic proliferations. <i>Histopathology</i> , 2020, 77, 984-988.	2.9	6
48	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
49	Diagnostic Accuracy of a Defined Immunophenotypic and Molecular Genetic Approach for Peripheral T/NK-Cell Lymphomas: A North American PTCL Study Group Project. <i>Blood</i> , 2012, 120, 1545-1545.	1.4	6
50	Case report and literature review: cardiac tamponade as a complication of pericardial extramedullary hematopoiesis. <i>Cardiovascular Pathology</i> , 2016, 25, 371-374.	1.6	5
51	Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias). <i>American Journal of Clinical Pathology</i> , 2019, 152, 302-321.	0.7	5
52	Myelodysplastic syndromes with no somatic mutations detected by next-generation sequencing display similar features to myelodysplastic syndromes with detectable mutations. <i>American Journal of Hematology</i> , 2021, 96, E420-E423.	4.1	5
53	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. <i>Blood Advances</i> , 2020, 4, 5089-5092.	5.2	5
54	Many faces of the same myeloid neoplasm: a case of leukaemia cutis with mixed histiocytic and Langerhans cell differentiation. <i>Journal of Clinical Pathology</i> , 2019, 72, 93-96.	2.0	4

#	ARTICLE	IF	CITATIONS
55	Developmental Ontogeny of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Revealed By Recurrent High Burden Clonal Hematopoiesis, Including in "Skin-Only" Disease. <i>Blood</i> , 2018, 132, 2755-2755.	1.4	4
56	<scp>Epstein-Barr</scp> virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. <i>International Journal of Cancer</i> , 2022, 150, 753-760.	5.1	4
57	A novel in vivo model for studying conditional dual loss of BLIMP1 and p53 in B cells, leading to tumor transformation. <i>American Journal of Hematology</i> , 2017, 92, E138-E145.	4.1	3
58	Generation of Models of Human Hematologic Malignancies Using CRISPR Genome Engineering. <i>Blood</i> , 2016, 128, 741-741.	1.4	3
59	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	1.4	3
60	Harmonization of the Essentials: Matching Diagnostics to Treatments for Global Oncology. <i>JCO Global Oncology</i> , 2020, 6, 1352-1356.	1.8	2
61	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. <i>Blood</i> , 2015, 126, 3252-3252.	1.4	2
62	Physical Interaction Between Mutant Calreticulin and the Thrombopoietin Receptor Is Required for Hematopoietic Transformation. <i>Blood</i> , 2015, 126, LBA-4-LBA-4.	1.4	2
63	Blastic Plasmacytoid Dendritic Cell Neoplasm: First Case Report From Rwanda and Review of the Literature. <i>Journal of Global Oncology</i> , 2019, 5, 1-6.	0.5	1
64	Concomitant classic Hodgkin lymphoma and schistosomiasis. <i>American Journal of Hematology</i> , 2019, 94, 840-841.	4.1	1
65	Talazoparib Treatment Preferentially Depletes Cohesin-Mutant Clones in New In Vivo Models of Cohesin-Mutant Myeloid Diseases. <i>Blood</i> , 2019, 134, 560-560.	1.4	1
66	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. <i>Blood</i> , 2020, 136, 13-14.	1.4	1
67	T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2016, 128, 3015-3015.	1.4	1
68	Clinical Characteristics of GNB1 and GNAS Mutations in an Unselected Cohort of 6,343 Patients with Hematologic Abnormalities. <i>Blood</i> , 2018, 132, 1819-1819.	1.4	1
69	Incidence and Clinical Features of Extramedullary Multiple Myeloma in Patients Who Underwent Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 5746-5746.	1.4	0
70	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , 2015, 126, 2655-2655.	1.4	0
71	B and T-Cell Lymphoma Patient-Derived Xenografts Recapitulate Aspects of Disease Biology and Progression and Represent Novel Tools for Preclinical Drug Development. <i>Blood</i> , 2015, 126, 4001-4001.	1.4	0
72	Pediatric-Type Nodal Follicular Lymphoma in Children and Adults Is Nearly Genetically Silent and Biologically Distinct from Typical Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3925-3925.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Systematic STAT3 Mutation Testing Identifies Patients with Unsuspected T-Cell Large Granular Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 919-919.	1.4	0
74	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. <i>Blood</i> , 2016, 128, 4169-4169.	1.4	0
75	Flow cytometry minimal residual disease assessment in peripheral blood of adult acute lymphoblastic leukemia patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18517-e18517.	1.6	0
76	Recurrent Genetic HLA Loss in Acute Myeloid Leukemia Relapsed after Matched Unrelated Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2018, 132, 817-817.	1.4	0
77	Clinical Utility of Routine Targeted Next-Generation Sequencing of Peripheral Blood in the Evaluation of Patients with Cytopenias. <i>Blood</i> , 2018, 132, 3090-3090.	1.4	0
78	Targeted Inhibition of CD47-Sirp Alpha Requires Fc-Fc Gamma Receptor Interactions to Maximize Phagocytosis in T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 339-339.	1.4	0